Top Biotech Stock Gainers: ITRM, FRLN, IMAB
5:10 pm Friday, May 28th, 2021
Following are the notable big biotech gainers on Friday:-
Iterum Therapeutics PLC (NASDAQ: ITRM) is the notable gainer and soared 20% as the company ) has concluded a late-cycle meeting with the FDA related to its application for sulopenem etzadroxil/probenecid.
Sulopenem is under review as a treatment for uncomplicated urinary tract infections in patients with a quinolone non-susceptible pathogen. The agency determined that an Advisory Committee meeting is not currently necessary and is continuously working toward the action date of July 25.
Freeline Therapeutics Holdings (NASDAQ: FRLN) stock gained over 11.70% to $10.96. Freeline Therapeutics, is working on gene therapies for debilitating, chronic diseases, including bleeding disorders. The company has four drugs in the development pipeline, two as treatments for hemophilia, one for Fabry disease, and one for Gaucher disease. Freeline follows a proprietary liver-based investigational gene therapy approach in its research.
Three of the company’s drug candidates are in clinical trials. FLT190, under investigation as a treatment for Fabry disease, is in a Phase 1/2 dose-finding study, with data expected to be presented before the end of this year. FLT201 is also in a Phase 1/2 dose-finding study, for Gaucher disease. This study is expected to be in the clinic before the end of this year. Finally, FLT180a, a drug candidate under investigation as a treatment for hemophilia B, is in a Phase 1/2 dose-confirmation study, and is on track to initiate trial sites by year’s end.
I-Mab (NASDAQ: IMAB) is up 11% at $83.49. The company today announced its participation in the following conferences in June. Details of the conferences and management presentation are as follows
Jefferies Healthcare Conference (Virtual), Fireside chat: Tuesday, June 1, 2021 at 3:00 p.m.ET. Speaker: Dr. Jingwu Zang, Founder, Chairman and Director
